|Assessment Status||Rapid Review complete|
|Indication||For the treatment and prevention of COVID-19.|
|Rapid review commissioned||20/12/2021|
|Rapid review completed||01/02/2022|
|Rapid review outcome||On the basis of current evidence, the NCPE recommends that casirivimab/imdevimab not be considered for reimbursement at this time*.|
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.